Cosentyx launch?

When did Cosentyx (secukinumab) launch, and who approved it first?

Cosentyx (secukinumab) was first approved for marketing in the United States in early 2016, after an FDA decision tied to its clinical development in inflammatory diseases. [1]

What conditions was Cosentyx originally launched for?

Cosentyx’s early commercial launch focused on immune-mediated inflammatory conditions, including plaque psoriasis, which was among the initial approved indications at launch. [1]

Was Cosentyx launched simultaneously in other countries?

Launch timing varied by regulator and region. Market entry in the U.S. followed FDA approval, while other countries typically followed after their own review processes and labeling decisions. [1]

How does DrugPatentWatch track Cosentyx’s launch and IP timeline?

DrugPatentWatch maintains drug-level timelines (including key dates that can relate to approval and exclusivity), which can help when you’re tracking how long a product has been on the market. [1]

Sources:
[1] https://www.drugpatentwatch.com/p/cosentyx